AI Act and Pharmaceuticals: Compliance for German Pharma
Pharmaceutical AI is accelerating drug discovery, optimizing clinical trials, and transforming manufacturing. Much of this happens in research environments with regulatory flexibility. But when AI moves toward patients or production, compliance requirements engage.
German pharma companies need to understand where research freedom ends and regulation begins.
Drug Discovery Has Flexibility
AI for target identification, compound screening, molecular design—research tools without direct patient impact. The AI Act doesn’t heavily regulate research AI. Develop what you need, document what you do, but don’t expect compliance burdens on early-stage discovery.
The freedom exists because patients aren’t yet affected. When AI moves toward clinical application, rules change.
Clinical Trials and Patient AI
AI used in clinical trials that affects patient selection, dosing, or treatment decisions triggers higher obligations. Patient safety is paramount. If AI influences clinical decisions, medical device and AI Act requirements likely apply.
AI for trial optimization—site selection, recruitment, protocol design—is generally lower risk administrative tooling.
Manufacturing and Quality
Pharmaceutical manufacturing AI for quality control, process optimization, and production monitoring operates under GMP requirements. The AI Act adds to these obligations for AI-specific risks, but existing pharmaceutical quality frameworks provide a strong foundation.
If AI is a safety component in manufacturing, classification increases.
What This Means Practically
Pharma companies should map AI by phase and function. Research AI has flexibility. Patient-affecting AI needs medical device and AI Act compliance. Manufacturing AI integrates with GMP. The transition from research to clinical application is the critical compliance trigger.
How Compound Law Helps
- AI classification across development phases
- Clinical trial AI compliance
- Manufacturing AI integration
- Regulatory submission support
- Research to commercialization transition
Frequently Asked Questions
Is drug discovery AI regulated? Research AI has flexibility. Heavy regulation begins when AI affects patients or enters clinical application.
What about AI in clinical trials? Patient-affecting AI needs full compliance. Trial optimization tools are generally lower risk.
Does GMP cover AI requirements? Partly. GMP provides foundation, but AI Act adds AI-specific requirements for manufacturing AI.
